Compare

Fagron NV/€FAGR

1D1W1M3M6MYTD1Y5YMAX

About Fagron NV

Fagron NV is a pharmaceutical company specializing in pharmaceutical compounding, providing personalized medical solutions to hospitals, pharmacies, clinics, and patients across more than 30 countries. The company operates through three segments: Essentials, offering pharmaceutical raw materials and equipment; Brands, developing innovative compounding concepts and formulations; and Compounding Services, delivering ready-to-use medications from its sterile and non-sterile facilities. Founded in 1990 in Rotterdam, the Netherlands, Fagron has expanded its operations globally, with its registered office in Nazareth, Belgium, and operational headquarters in Rotterdam. The company's strategic focus on innovation and quality has enabled it to establish a significant presence in the pharmaceutical compounding market.
Ticker
€FAGR
Sector
Health
Primary listing
BSE
Employees
4,880
Headquarters
Nazareth, Belgium
Website
www.fagron.com

Fagron NV Metrics

BasicAdvanced
€1.7B
18.74
€1.25
0.38
€0.28
1.20%

What the Analysts think about Fagron NV

Analyst ratings (Buy, Hold, Sell) for Fagron NV stock.
Analyst projections of the future price of Fagron NV stock.

Bulls say / Bears say

Q3 revenue rose 23.2%, with organic growth of 3.4% led by EMEA and Latin America, and Fagron maintained its FY 2026 revenue and adjusted EBITDA margin guidance. This points to demand across several regions, though acquisitions also supported reported growth. (Fagron Investors)
Capacity expansion could provide another growth leg: management says the new Tampa site has about $100 million of revenue potential, while the Wichita and Las Vegas projects could add $350 million. The return depends on Fagron filling that capacity as it comes on stream. (Roic AI)
In the first half, adjusted EBITDA rose 12.7% to €107.1 million and operating cash flow increased 10.8% to €58.1 million. That suggests the business is generating cash alongside sales growth. (Fagron Investors)
The FDA issued a warning letter after inspecting Fagron’s Boston sterile facility, following a voluntary recall of selected products made using third-party IV bags. Production continues without material impact, but remediation and further regulatory scrutiny remain risks. (Fagron Investors)
Fagron’s adjusted EBITDA margin fell 60 basis points year on year to 19.4% in the first half, as lower North American compounding volumes and acquisition and product mix weighed on profitability. If margins do not recover, earnings may lag sales growth. (Roic AI, Fagron Investors)
Net debt rose €222.1 million to €505.4 million by June, and leverage reached 2.1 times EBITDA, largely due to acquisition payments and working-capital movements. Higher debt and financing costs could constrain further deals or weigh on earnings if cash generation weakens. (Roic AI)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2026.

Fagron NV Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Fagron NV Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Fagron NV

AllUSDEURGBP
Funds
Fund name
Fund size
€FAGR weighting
Xtrackers MSCI Europe Small Cap£XXSC
$3.6B0.11%
Xtrackers MSCI Europe Small Cap€DX2J
$3.6B0.11%
Vanguard ESG Developed Europe All Cap£V3EA
€125M0.02%
Vanguard ESG Developed Europe All Cap£V3EL
€35M0.02%
iShares MSCI World Small Cap£WLDS
$9B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.